Weighing the evidence on GLP1s and venous thromboembolism
Open Access
- 27 May 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (10) , 2458-2459
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulationBlood Advances, 2025
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without DiabetesAnnals of Internal Medicine, 2025
- The Risk of Incident Venous Thromboembolism Attributed to Overweight and Obesity: The Tromsø StudyThrombosis and Haemostasis, 2023
- Target Trial EmulationJAMA, 2022
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trialsCardiovascular Research, 2021